Cited 0 times in
Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽영란 | - |
dc.contributor.author | 심재광 | - |
dc.contributor.author | 조장은 | - |
dc.date.accessioned | 2015-04-23T16:52:43Z | - |
dc.date.available | 2015-04-23T16:52:43Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0862-8408 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101399 | - |
dc.description.abstract | Remifentanil is a commonly used opioid in anesthesia with cardioprotective effect in ischemia-reperfused (I/R) heart. We evaluated the influence of remifentanil on myocardial infarct size and expressions of proteins involved in apoptosis in I/R rat heart following various time protocols of remifentanil administration. Artificially ventilated anesthetized Sprague-Dawley rats were subjected to a 30 min of left anterior descending coronary artery occlusion followed by 2 h of reperfusion. Rats were randomly assigned to one of five groups; Sham, I/R only, remifentanil preconditioning, postconditioning and continuous infusion group. Myocardial infarct size, the phosphorylation of ERK1/2, Bcl2, Bax and cytochrome c and the expression of genes influencing Ca2+ homeostasis were assessed. In remifentanil-administered rat hearts, regardless of the timing and duration of administration, infarct size was consistently reduced compared to I/R only rats. Remifentanil improved expression of ERK1/2 and anti-apoptotic protein Bcl2, and expression of sarcoplasmic reticulum genes which were significantly reduced in the I/R rats only. Remifentanil reduced expression of pro-apoptotic protein, Bax and cytochrome c. These suggested that remifentanil produced cardioprotective effect by preserving the expression of proteins involved in anti-apoptotic pathways, and the expression of sarcoplasmic reticulum genes in I/R rat heart, regardless of the timing of administration. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 347~356 | - |
dc.relation.isPartOf | PHYSIOLOGICAL RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adjuvants, Anesthesia/administration & dosage | - |
dc.subject.MESH | Adjuvants, Anesthesia/pharmacology* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Apoptosis/drug effects* | - |
dc.subject.MESH | Blotting, Western | - |
dc.subject.MESH | Calcium/metabolism | - |
dc.subject.MESH | Cell Survival/drug effects | - |
dc.subject.MESH | Cytochromes c/metabolism | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Gene Expression Regulation/drug effects | - |
dc.subject.MESH | Hemodynamics/drug effects | - |
dc.subject.MESH | Homeostasis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mitogen-Activated Protein Kinase 1/metabolism | - |
dc.subject.MESH | Mitogen-Activated Protein Kinase 3/metabolism | - |
dc.subject.MESH | Myocardial Infarction/genetics | - |
dc.subject.MESH | Myocardial Infarction/metabolism | - |
dc.subject.MESH | Myocardial Infarction/pathology | - |
dc.subject.MESH | Myocardial Infarction/physiopathology | - |
dc.subject.MESH | Myocardial Infarction/prevention & control* | - |
dc.subject.MESH | Myocardial Reperfusion Injury/genetics | - |
dc.subject.MESH | Myocardial Reperfusion Injury/metabolism | - |
dc.subject.MESH | Myocardial Reperfusion Injury/pathology | - |
dc.subject.MESH | Myocardial Reperfusion Injury/physiopathology | - |
dc.subject.MESH | Myocardial Reperfusion Injury/prevention & control* | - |
dc.subject.MESH | Myocardium/metabolism | - |
dc.subject.MESH | Myocardium/pathology* | - |
dc.subject.MESH | Phosphorylation | - |
dc.subject.MESH | Piperidines/administration & dosage | - |
dc.subject.MESH | Piperidines/pharmacology* | - |
dc.subject.MESH | Proto-Oncogene Proteins c-bcl-2/metabolism | - |
dc.subject.MESH | RNA, Messenger/metabolism | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Reverse Transcriptase Polymerase Chain Reaction | - |
dc.subject.MESH | Sarcoplasmic Reticulum/metabolism | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | bcl-2-Associated X Protein/metabolism | - |
dc.title | Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anesthesiology (마취통증의학) | - |
dc.contributor.googleauthor | H. S. KIM | - |
dc.contributor.googleauthor | J. E. CHO | - |
dc.contributor.googleauthor | S. W. HONG | - |
dc.contributor.googleauthor | S. O. KIM | - |
dc.contributor.googleauthor | J. K. SHIM | - |
dc.contributor.googleauthor | Y. L. KWAK | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00172 | - |
dc.contributor.localId | A02205 | - |
dc.contributor.localId | A03893 | - |
dc.relation.journalcode | J03213 | - |
dc.identifier.eissn | 1802-9973 | - |
dc.identifier.pmid | 19681651 | - |
dc.subject.keyword | Anti-apoptosis | - |
dc.subject.keyword | Cardioprotection | - |
dc.subject.keyword | Ischemia/ reperfusion injury | - |
dc.subject.keyword | Remifentanil | - |
dc.contributor.alternativeName | Kwak, Young Lan | - |
dc.contributor.alternativeName | Shim, Jae Kwang | - |
dc.contributor.alternativeName | Cho, Jang Eun | - |
dc.contributor.affiliatedAuthor | Kwak, Young Lan | - |
dc.contributor.affiliatedAuthor | Shim, Jae Kwang | - |
dc.contributor.affiliatedAuthor | Cho, Jang Eun | - |
dc.citation.volume | 59 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 347 | - |
dc.citation.endPage | 356 | - |
dc.identifier.bibliographicCitation | PHYSIOLOGICAL RESEARCH, Vol.59(3) : 347-356, 2010 | - |
dc.identifier.rimsid | 51029 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.